secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009124
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter
--------------------------------------------------------------------------------

- Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.
- Net loss $15.6M (increase 124% YoY); operating expenses $17.8M, up 10%.
- Raised $27.4M post-Q1: $11.7M private placement, $2.7M ATM, $13M net from $25M debt facility.
- Restructured Indi milestone payments, reducing 2022 pay by $7.5M and 2023 by $7.2M.
- Reaffirmed FY2022 total revenue outlook of $37.5M-$39.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/0000950170-22-009124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/bdsx-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer